Greenwich LifeSciences, Inc. (GLSI)

NASDAQ: GLSI · IEX Real-Time Price · USD
12.98
-0.72 (-5.26%)
At close: Dec 9, 2022 4:00 PM
13.48
+0.50 (3.85%)
After-hours: Dec 9, 2022 6:43 PM EST
-5.26%
Market Cap 176.02M
Revenue (ttm) n/a
Net Income (ttm) -7.40M
Shares Out 12.82M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 28,964
Open 13.78
Previous Close 13.7
Day's Range 12.85 - 13.84
52-Week Range 6.82 - 33.8
Beta 3.71
Analysts Buy
Price Target 79.56 (+512.9%)
Earnings Date Nov 21, 2022

About GLSI

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 ... [Read more]

Industry Biotechnology
IPO Date Sep 25, 2020
Employees 3
Stock Exchange NASDAQ
Ticker Symbol GLSI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for GLSI stock is "Buy." The 12-month stock price forecast is 79.56, which is an increase of 512.94% from the latest price.

Price Target
$79.56
(512.94% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

STAFFORD, Texas--( BUSINESS WIRE )--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to pr...

1 week ago - Business Wire

GLSI, AVTE: The Top 5 Short Squeeze Stocks to Watch This Week

Short-squeeze stocks continue to be a big deal for speculative traders and we're helping them out with a list to keep in mind this week! That list comes from Fintel and its Short Squeeze Leaderboard.

Other symbols: AVTEBEATNERVVORB
1 month ago - InvestorPlace

TOPS, SURG: The Top 5 Short Squeeze Stocks This Week

Source: g0d4ather / Shutterstock.com Short squeeze stocks are still popular with speculative traders and that has us going over the top ones to keep an eye on this week! Luckily, Fintel has traders cove...

Other symbols: NERVSURGTOPSWEBR
1 month ago - InvestorPlace

GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This Week

Source: g0d4ather / Shutterstock.com Investors are still interested in short squeeze stocks and we've got them covered with the ones to watch this week! Fintel is offering up a list of the short squeeze...

Other symbols: APRNPETZSURGSYRS
2 months ago - InvestorPlace

NRBO, FAZE: The Top 5 Short Squeeze Stocks to Watch This Week

Source: Alextype/Shutterstock.com Traders continue to show interest in short squeeze stocks this week as they seek out likely targets to push higher. This has us checking out Fintel's Short Squeeze Lead...

Other symbols: FAZENRBONERVSURG
2 months ago - InvestorPlace

ATHX, PETS: The Top 5 Short Squeeze Stocks to Watch This Week

Source: g0d4ather / Shutterstock.com We're starting off another week with a deep dive into the short squeeze stocks to watch! Short squeeze stocks have been popular with traders in recent months as they...

Other symbols: ATHXPETZMICSWEBR
2 months ago - InvestorPlace

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

3 months ago - Business Wire

7 Short-Term Stocks to Buy for a Quick Profit

While most people don't like to see red ink in their investment portfolios, at the same time, that negative print comes from volatility — and volatility in either direction presents opportunities for sh...

Other symbols: CMPOCSSEFATSNDLTBLT
4 months ago - InvestorPlace

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

4 months ago - Business Wire

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Financing Strategy & Corporate Update

4 months ago - Business Wire

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by 32.95% to $11.46 Tuesday afternoon after the FDA removed the clinical hold on the company's Flamingo-01 Phase 3 trial of GP2. Green...

4 months ago - Benzinga

Why Is Greenwich Lifesciences (GLSI) Stock Up Today?

Greenwich Lifesciences (GLSI) stock is heading higher on Tuesday after the FDA lifted a hold on a Phase III clinical trial. The post Why Is Greenwich Lifesciences (GLSI) Stock Up Today?

4 months ago - InvestorPlace

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

4 months ago - Business Wire

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Suspension of Share Repurchase Program

4 months ago - Business Wire

Greenwich LifeSciences to Resume Stock Repurchase Program

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Resume Stock Repurchase Program

6 months ago - Business Wire

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

6 months ago - Business Wire

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

7 months ago - Business Wire

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Prevent...

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

7 months ago - Business Wire

Recession Fears are Creating a Golden Opportunity for Biotech Stocks

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech Sto...

8 months ago - InvestorPlace

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

9 months ago - Business Wire

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

10 months ago - Business Wire

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

10 months ago - Business Wire

3 Stocks Insiders Are Buying on Market Turbulence

When insiders buy a stock, you should take it as a sign that they think good news is about to come out. Here are three to watch closely.

Other symbols: LGVN
10 months ago - InvestorPlace

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders fo...

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

10 months ago - Business Wire

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

11 months ago - Business Wire